Effectiveness and Safety of Etanercept in Paediatric Patients with Plaque-Type Psoriasis: Real-World Evidence

Author:

Narbutt Joanna1,Jakubczak Zofia2,Wasiewicz-Ciach Paulina2,Wojtania Joanna2,Krupa Katarzyna1,Sobolewska-Sztychny Dorota13,Ciążyńska Magdalena3,Kołt-Kamińska Marta4,Reich Adam4ORCID,Skibińska Małgorzata1,Lesiak Aleksandra13

Affiliation:

1. Department of Dermatology, Paediatric Dermatology and Oncology, Medical University of Lodz, 90-419 Lodz, Poland

2. Students’ Scientific Association of Experimental, Clinical and Surgical Dermatology, Medical University of Lodz, 91-347 Lodz, Poland

3. Laboratory of Autoinflammatory, Genetic and Rare Skin Disorders, Department of Dermatology, Pediatric Dermatology and Oncology, Medical University of Lodz, 91-347 Lodz, Poland

4. Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, 35-055 Rzeszow, Poland

Abstract

Background: Psoriasis is a chronic, multisystemic, inflammatory disease affecting approximately 1% of children and significantly reducing their health-related quality of life. Etanercept is a biologic fusion protein-blocking TNF-α and belongs to one of the biologics used among the children population. The purpose of this study was to assess the effectiveness and safety profile of etanercept in paediatric patients with plaque-type psoriasis. Material and methods: The outcome of the treatment was evaluated based on Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and Children’s Dermatology Life Quality Index (CDLQI). Achievement of at least PASI75 at week 16 was assessed as an adequate response to therapy, which was the primary endpoint. Results: Forty-three paediatric patients were included in the study, 24 females and 19 males. The average age at inclusion into our study was 13 years. At baseline, the mean PASI score, BSA, and CDLQI were 16.3 ± 6.5, 22.3 ± 12.2%, and 17.4 ± 5.3, respectively. At week 16, 90.7% of patients achieved PASI 50, 79.1% achieved PASI 75, and 46.5% attained PASI 90. There was also a decrease in mean BSA and CDLQI values to 3.5 ± 3.8 and 5.4 ± 5.7, respectively. Conclusions: Etanercept proved to be effective, safe, and well-tolerated among the paediatric population with psoriasis.

Funder

Dermatology, Paediatric Dermatology and Oncology Clinic, Medical University of Lodz, Poland

Publisher

MDPI AG

Reference34 articles.

1. Psoriasis;Weigle;Am. Fam. Physician,2013

2. Diotallevi, F., Simonetti, O., Rizzetto, G., Molinelli, E., Radi, G., and Offidani, A. (2022). Biological treatments for paediatric psoriasis: State of the art and future perspectives. Int. J. Mol. Sci., 23.

3. Pathogenesis and clinical features of psoriasis;Griffiths;Lancet,2007

4. Parental stress and quality of life in chronic childhood dermatoses: A review;Datta;J. Clin. Aesthet. Dermatol.,2021

5. Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis;Kivelevitch;Biologics.,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3